Biotech M&A Trends and IPO Window Activity
2026 YTD M&A value has surpassed FY25, but the focus is narrow, targeting portfolio gaps, platform control, and scarce category entry rather than broad biotech exposure. Apnimed's filing for a U.S. IPO, while its sleep apnea drug is under FDA review, signals an open IPO window for late-stage companies with clear regulatory catalysts.
Dan Bone - Morgan Stanley ·
🔗 fonte Hinge Health (HNGE) Estimates and Price Target Raised to $108
Morgan Stanley raised Hinge Health's price target to $108 (from $72) and increased CY26/27/28 revenue estimates by 2%/4%/7% to $821mn/$1,001mn/$1,182mn, and EBIT estimates by 3%/9%/12% to $222mn/$300mn/$378mn, respectively. This follows a 45% Y/Y increase in Q2 app downloads.
Dan Bone - Morgan Stanley ·
🔗 fonte ResMed (RMD) Issues Ventilator Safety Notice, Citi Downgrades
ResMed issued a Field Safety Notice for its Astral 100 and Astral 150 Ventilators. Citi downgraded the stock, and an analyst noted the impact on device revenue is likely small (<10%), but could be an incremental EPS headwind.
Germany Approves Healthcare Cost Bill Despite Drugmaker Pushback
Germany's upper house approved a bill to control statutory health-insurance costs, which drugmakers criticize as a headwind to pharma investment in Germany and broader European launch economics, highlighting a widening global pricing conflict.
Dan Bone - Morgan Stanley ·
🔗 fonte AstraZeneca (AZN) CEO Interview Highlights Strategic Decisions and Succession Focus
AstraZeneca CEO Pascal Soriot stated that walking away from the Pfizer deal was the right decision and that R&D continues in China and the US, with a strong focus on succession planning.
Dan Bone - Morgan Stanley
FDA Resumes Releasing Pharma Rejection Letters with New CRL Batch
The FDA posted 14 new Complete Response Letters (CRLs), indicating a continued push for transparency regarding negative regulatory decisions after a previous pause due to industry objections.
Dan Bone - Morgan Stanley ·
🔗 fonte Businesses Racing into Peptide Gray Market Amid Regulatory Uncertainty
Doctors, telehealth companies, med spas, and venture investors are increasingly involved in injectable peptides despite regulatory uncertainty, creating a 'wellness and longevity gold rush' for products largely unapproved for human consumption in the U.S.
Dan Bone - Morgan Stanley ·
🔗 fonte Hidradenitis Suppurativa (HS) Treatment Landscape: New Therapies Emerge
HS is a painful skin condition affecting 2.7M people in the US, with advanced biologic drug use limited. Newer IL-17 drugs have improved treatment, but significant opportunity remains for better, faster, or oral medicines. UCB’s Bimzelx is a leading drug. Novartis’ remibrutinib is a credible near-term threat, with Phase 3 HS data (H2'26) as a key upside catalyst (>80% success, >$1bn peak sales). AbbVie (lutikizumab, Rinvoq), Moonlake (sonelokimab), Incyte (Opzelura, povorcitinib), and Avalo Therapeutics (abdakibart) are also developing treatments.
Dan Bone - Morgan Stanley
Eli Lilly (LLY) Mounjaro+Zepbound Script Tracker Shows Upside to Estimates
Weekly TRx/NRx scripts for Mounjaro were ~844,100/393,100 and for Zepbound were ~680,400/369,700. Morgan Stanley sees ~4% upside to 2026 M+Z estimates.
Dan Bone - Morgan Stanley ·
🔗 fonte Insmed (INSM) Brinsupri Weekly Script Analysis Tracks Above Consensus
Symphony Rx data shows 1,328 scripts for Brinsupri for the week of 7/03/26, suggesting 2Q26 sales of $292.2M, above consensus estimates.
Dan Bone - Morgan Stanley ·
🔗 fonte Alnylam Pharmaceuticals (ALNY) Amvuttra Sales Tracking Inline with Consensus
Amvuttra and total TTR sales are tracking in line with consensus for 2Q26, with monthly TTR script volume increasing +6% in June and +20% Y/Y. The company expects growth to accelerate in 2Q26 and reiterates FY26 TTR sales guidance.
Dan Bone - Morgan Stanley ·
🔗 fonte Sino Biopharmaceutical (1177.HK) Risk Reward Update Ahead of 1H26 Results
Model adjustments ahead of 1H26 results, lowering generic+biosimilar sales forecasts amid new sales rep policies and upcoming VBP.
Dan Bone - Morgan Stanley ·
🔗 fonte China Healthcare Sector Sentiment Rises Post-Revised Essential Medicines List
China healthcare sector sentiment edged up after the publication of its revised National Essential Medicines List.
Dan Bone - Morgan Stanley
Australia Healthcare Medicare Statistics for May-26 Released
Australian Medicare statistics for May-26 were released, noting one less working day compared to May-25.
Dan Bone - Morgan Stanley
Pre-Market Movers: QTTB, AGEN, CNMD, RMD, JAZZ Highlights
QTTB (+66.8%) saw positive 36-week topline results in alopecia. AGEN (+41.8%) announced a $340M private placement for its ROBBIN trial. CNMD (+3.1%) is reportedly weighing a sale after takeover interest. RMD (-0.0%) faced a Field Safety Notice for ventilators and a Citi downgrade. JAZZ (-0.0%) received a CRL for its TRN-257 NDA.
Dan Bone - Morgan Stanley
📄 Publicações e eventos
BioPharma Beat – SMID Biotech
A Morgan Stanley podcast discussing SMID biotech, Operation TRIALBlazer, single stocks to buy, and 3Q catalysts.
Dan Bone - Morgan Stanley ·
🔗 fonte RXRX CEO Lunch in NYC
An investor lunch with the CEO of RXRX in NYC on July 13th.
Dan Bone - Morgan Stanley
HS KOL Call w/ Sarita & Terence
A Key Opinion Leader (KOL) call on Hidradenitis Suppurativa with Sarita & Terence on July 14th.
Dan Bone - Morgan Stanley
BIIB/IONS KOL Call for Diranersen Ph2 Alzheimer’s Data at AAIC
A Key Opinion Leader (KOL) call on July 14th to discuss Biogen/Ionis's Diranersen Phase 2 Alzheimer’s Data at AAIC.
Dan Bone - Morgan Stanley
Life Science Tools/Diagnostics 2Q EPS Preview Lunch w/ Kallum
A lunch event on July 15th with Kallum for a Q2 EPS preview for Life Science Tools/Diagnostics (currently full).
Dan Bone - Morgan Stanley
BioPharma 2Q EPS Preview Lunch w/ Terence Flynn
A lunch event on July 16th with Terence Flynn for a Q2 EPS preview for BioPharma.
Dan Bone - Morgan Stanley
JNJ Post-2Q EPS Management Call w/ Terence Flynn
A management call on July 17th with Terence Flynn to discuss Johnson & Johnson's post-Q2 EPS results.
Dan Bone - Morgan Stanley
MS Healthcare Conference - 1x1 Deadline
The deadline for 1x1 meetings at the Morgan Stanley Healthcare Conference, scheduled for September 14-16 in NYC, is July 17th.
Dan Bone - Morgan Stanley
SMID Biotech Ideas Exchange Lunch – Commercial Stage
A lunch event on July 27th for SMID Biotech Ideas Exchange, focusing on commercial stage ideas.
Dan Bone - Morgan Stanley
GENB NYC NDR w/ 1x1 + Small Group Lunch
A Non-Deal Roadshow (NDR) for Generate Biomedicines (GENB) in NYC on July 29th, including 1x1 meetings and a small group lunch.
Dan Bone - Morgan Stanley
Expert Call: Call on Hidradenitis Suppurativa (Bimzelx, Cosentyx and evolving treatment landscape)
A live expert call on Tuesday, July 14, 2026, hosted by Morgan Stanley analysts Sarita Kapila & Terence Flynn with Dr. Paul Yamauchi, discussing the evolving treatment landscape for Hidradenitis Suppurativa, focusing on drugs from UCB, Novartis, AbbVie, Moonlake, Incyte, and Avalo Therapeutics. No replay will be available.
Dan Bone - Morgan Stanley ·
🔗 fonte UCB S.A.: Near-Term Support, Second-Half Pressure (5 Jun 2026)
A research report by Morgan Stanley on UCB S.A., dated June 5, 2026, discussing near-term support and second-half pressure.
Dan Bone - Morgan Stanley ·
🔗 fonte Novartis AG: Rhapsido (remibrutinib): the next >$5bn drug (27 Oct 2025)
A research report by Morgan Stanley on Novartis AG, dated October 27, 2025, highlighting Rhapsido (remibrutinib) as a potential >$5bn drug.
Dan Bone - Morgan Stanley ·
🔗 fonte Incyte Corp: 1Q26 Earnings - Progress Across Multiple Pipeline Verticals Supports Post-Jakafi Narrative (28 Apr 2026)
A research report by Morgan Stanley on Incyte Corp, dated April 28, 2026, discussing 1Q26 earnings and pipeline progress supporting the post-Jakafi narrative.
Dan Bone - Morgan Stanley ·
🔗 fonte Novartis AG: Unlocking pipeline optionality: 9 shots on goal (26 Mar 2026)
A research report by Morgan Stanley on Novartis AG, dated March 26, 2026, detailing pipeline optionality with 9 key development programs.
Dan Bone - Morgan Stanley ·
🔗 fonte What's Next? Dinner | AI, Drug Discovery, and Life Science Tools
An exclusive dinner hosted by Morgan Stanley on Monday, July 20th, 2026, featuring senior thought leaders to discuss market trends and the outlook in AI, Drug Discovery, and Life Science Tools.
Dan Bone - Morgan Stanley ·
🔗 fonte